Summary
PROJECT SUMMARY Ovarian cancer is the deadliest gynecological cancer, in part because there is no widely used screening test and 80% of tumors are diagnosed at a late stage. Though ovarian cancer screening has the poten>al to diagnose tumors at early stages when pa>ent outcomes are far be?er (90% survival for stage I cancer vs. <20% for stage III/IV), recent screening trials of protein biomarkers have failed to show a mortality benefit. This has highlighted three main challenges in ovarian cancer screening: (1) Avoiding false posi>ve results leading to unnecessary procedures in a disease with l
